Is NUVB or PROK more profitable?

Nuvation Bio has a net margin of -88.18% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% ProKidney -10,288.39% N/A -27.39%

Does the media prefer NUVB or PROK?

In the previous week, Nuvation Bio had 9 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Nuvation Bio and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Nuvation Bio's score of 0.29 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or PROK?

In the previous week, BioCryst Pharmaceuticals had 13 more articles in the media than ProKidney. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat BioCryst Pharmaceuticals' score of 0.42 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, BHVN or PROK?

ProKidney has higher revenue and earnings than Biohaven. ProKidney is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A ProKidney $890K 609.74 -$68.99M -$0.55 N/A

Is BHVN or PROK more profitable?

Biohaven has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% ProKidney -10,288.39% N/A -27.39%

Does the media prefer BHVN or PROK?

In the previous week, Biohaven had 14 more articles in the media than ProKidney. MarketBeat recorded 16 mentions for Biohaven and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Biohaven's score of 0.25 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PROK or SRPT?

In the previous week, Sarepta Therapeutics had 7 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Sarepta Therapeutics and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Sarepta Therapeutics' score of 0.40 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PROK or KOD?

In the previous week, Kodiak Sciences had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Kodiak Sciences and 2 mentions for ProKidney. Kodiak Sciences' average media sentiment score of 1.36 beat ProKidney's score of 0.94 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ProKidney (PROK) Competitors

$1.82 +0.08 (+4.89%)

As of 10:47 AM Eastern

Compare

PROK vs. NUVB, BCRX, BHVN, SRPT, and KOD

Should you buy ProKidney stock or one of its competitors? ProKidney's main competitors and comparable companies include Nuvation Bio (NUVB), BioCryst Pharmaceuticals (BCRX), Biohaven (BHVN), Sarepta Therapeutics (SRPT), and Kodiak Sciences (KOD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProKidney compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Nuvation Bio had 9 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Nuvation Bio and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Nuvation Bio's score of 0.29 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Nuvation Bio currently has a consensus price target of $13.00, indicating a potential upside of 125.50%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 568.52%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Nuvation Bio has a net margin of -88.18% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
ProKidney	-10,288.39%	N/A	-27.39%

ProKidney has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	32.18	-$204.63M	-$0.44	N/A
ProKidney	$890K	609.74	-$68.99M	-$0.55	N/A

Summary

ProKidney beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.

How does ProKidney compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
ProKidney	-10,288.39%	N/A	-27.39%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than ProKidney. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.21	$263.86M	-$1.50	N/A
ProKidney	$890K	609.74	-$68.99M	-$0.55	N/A

In the previous week, BioCryst Pharmaceuticals had 13 more articles in the media than ProKidney. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat BioCryst Pharmaceuticals' score of 0.42 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.40, suggesting a potential upside of 151.08%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 568.52%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Summary

ProKidney beats BioCryst Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to Biohaven?

Biohaven (NYSE:BHVN) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

ProKidney has higher revenue and earnings than Biohaven. ProKidney is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
ProKidney	$890K	609.74	-$68.99M	-$0.55	N/A

In the previous week, Biohaven had 14 more articles in the media than ProKidney. MarketBeat recorded 16 mentions for Biohaven and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Biohaven's score of 0.25 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	3 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Biohaven has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
ProKidney	-10,288.39%	N/A	-27.39%

88.8% of Biohaven shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biohaven presently has a consensus target price of $18.69, suggesting a potential upside of 52.48%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 568.52%. Given ProKidney's stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

ProKidney beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Sarepta Therapeutics?

ProKidney (NASDAQ:PROK) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 568.52%. Sarepta Therapeutics has a consensus price target of $25.69, suggesting a potential upside of 28.21%. Given ProKidney's stronger consensus rating and higher probable upside, equities research analysts plainly believe ProKidney is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15

ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 7 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Sarepta Therapeutics and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.94 beat Sarepta Therapeutics' score of 0.40 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProKidney has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	609.74	-$68.99M	-$0.55	N/A
Sarepta Therapeutics	$1.97B	1.07	-$713.41M	-$2.90	N/A

51.6% of ProKidney shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -13.48% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Summary

ProKidney beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks.

How does ProKidney compare to Kodiak Sciences?

ProKidney (NASDAQ:PROK) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

In the previous week, Kodiak Sciences had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Kodiak Sciences and 2 mentions for ProKidney. Kodiak Sciences' average media sentiment score of 1.36 beat ProKidney's score of 0.94 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ProKidney presently has a consensus price target of $12.00, indicating a potential upside of 568.52%. Kodiak Sciences has a consensus price target of $48.14, indicating a potential upside of 50.49%. Given ProKidney's stronger consensus rating and higher probable upside, research analysts plainly believe ProKidney is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Kodiak Sciences has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Kodiak Sciences	N/A	-273.23%	-85.48%

ProKidney has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	609.74	-$68.99M	-$0.55	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Summary

ProKidney beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$542.66M	$3.85B	$7.21B	$15.01B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-3.26	14.51	273.55	25.41
Price / Sales	609.74	1,451.66	705.75	112.91
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	-0.53	15.32	10.45	6.22
Net Income	-$68.99M	-$22.78M	$3.49B	$357.96M
7 Day Performance	-2.97%	-0.42%	-0.38%	-0.13%
1 Month Performance	34.96%	0.65%	-0.13%	-3.34%
1 Year Performance	-31.49%	39.77%	19.26%	6.59%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	2.0021 of 5 stars	$1.80 +3.2%	$12.00 +568.5%	-29.0%	$542.66M	$890K	N/A	231	Gap Down
NUVB Nuvation Bio	3.0769 of 5 stars	$6.51 -1.6%	$13.00 +99.8%	+84.6%	$2.32B	$62.90M	N/A	60	News Coverage Analyst Forecast
BCRX BioCryst Pharmaceuticals	2.4484 of 5 stars	$8.81 -2.8%	$20.60 +133.8%	+6.0%	$2.32B	$940.61M	N/A	530
BHVN Biohaven	2.8426 of 5 stars	$15.02 +2.0%	$18.69 +24.4%	-10.5%	$2.22B	N/A	N/A	239
SRPT Sarepta Therapeutics	3.5602 of 5 stars	$22.02 +5.2%	$25.69 +16.7%	+18.6%	$2.21B	$2.20B	N/A	1,372	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. NUVB, BCRX, BHVN, SRPT, and KOD

How does ProKidney compare to Nuvation Bio?

Summary

How does ProKidney compare to BioCryst Pharmaceuticals?

Summary

How does ProKidney compare to Biohaven?

Summary

How does ProKidney compare to Sarepta Therapeutics?

Summary

How does ProKidney compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. NUVB, BCRX, BHVN, SRPT, and KOD

How does ProKidney compare to Nuvation Bio?

Do insiders & institutionals believe in NUVB or PROK?

Does the media prefer NUVB or PROK?

Which has more volatility and risk, NUVB or PROK?

Do analysts prefer NUVB or PROK?

Is NUVB or PROK more profitable?

Which has higher earnings and valuation, NUVB or PROK?

Summary

How does ProKidney compare to BioCryst Pharmaceuticals?

Is BCRX or PROK more profitable?

Do insiders & institutionals have more ownership in BCRX or PROK?

Which has stronger valuation & earnings, BCRX or PROK?

Does the media prefer BCRX or PROK?

Do analysts recommend BCRX or PROK?

Which has more risk & volatility, BCRX or PROK?

Summary

How does ProKidney compare to Biohaven?

Which has higher valuation & earnings, BHVN or PROK?

Does the media prefer BHVN or PROK?

Which has more volatility & risk, BHVN or PROK?

Is BHVN or PROK more profitable?

Do institutionals & insiders have more ownership in BHVN or PROK?

Do analysts rate BHVN or PROK?

Summary

How does ProKidney compare to Sarepta Therapeutics?

Do analysts rate PROK or SRPT?

Which has more volatility & risk, PROK or SRPT?

Does the media prefer PROK or SRPT?

Which has better earnings & valuation, PROK or SRPT?

Do insiders & institutionals have more ownership in PROK or SRPT?

Is PROK or SRPT more profitable?

Summary

How does ProKidney compare to Kodiak Sciences?

Which has more volatility and risk, PROK or KOD?

Does the media favor PROK or KOD?

Do insiders and institutionals believe in PROK or KOD?

Do analysts recommend PROK or KOD?

Is PROK or KOD more profitable?

Which has preferable earnings & valuation, PROK or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools